• Patient-Derived Gastric Cancer Assembloids Enhance Drug Resp

  2026-04-30

  This study establishes a novel patient-derived gastric cancer assembloid system that integrates matched tumor organoids with stromal cell subpopulations, closely replicating primary tumor microenvironment complexity. The model reveals the critical impact of stromal diversity on gene expression and variable drug sensitivity, providing a robust platform for personalized therapy research.

• ETV5 as an Epigenetic Prognostic Marker and Driver in Cancer

  2026-04-29

  This study provides the first comprehensive pan-cancer analysis linking high ETV5 expression to adverse prognosis and drug resistance, particularly via EZH2-mediated epigenetic modification in hepatocellular carcinoma. These findings underscore the potential of ETV5 as a biomarker and therapeutic target for epigenetic-based cancer interventions.

• Simvastatin (Zocor) as a Quantitative MoA Benchmark in Pheno

  2026-04-29

  Explore Simvastatin (Zocor) as a rigorous benchmark for mechanism-of-action profiling in high-content phenotypic assays. This article uniquely addresses best practices for experimental design and cross-line reproducibility, offering advanced guidance for researchers using Simvastatin in lipid and cancer biology.

• Tofacitinib Citrate (CP-690550): Advanced Insights in JAK3 R

  2026-04-28

  Explore the advanced role of Tofacitinib citrate (CP-690550 citrate) in immune regulation research, focusing on its selective JAK3 inhibition and nuanced vascular effects. This article provides practical, evidence-guided protocol insights and bridges recent cardiovascular findings to immunological assay design.

• Applied α-Amanitin: Precision RNA Polymerase II Inhibition W

  2026-04-28

  α-Amanitin from APExBIO empowers researchers to dissect transcriptional regulation with unmatched specificity. By enabling precise RNA polymerase II inhibition, it advances gene expression pathway analysis and developmental biology, as demonstrated in cutting-edge oocyte research.

• Bismuth Subsalicylate (A8382): Protocols for GI Disorder Res

  2026-04-27

  Bismuth Subsalicylate (SKU A8382) provides a high-purity, well-characterized reagent for inflammation and gastrointestinal disorder research, particularly in the context of diarrhea, upset stomach, and related pathway modulation assays. This compound is not suitable for diagnostic or therapeutic use and should be handled according to research-only protocols for maximum reproducibility.

• Imatinib hydrochloride: Optimizing Tyrosine Kinase Inhibitio

  2026-04-27

  Imatinib hydrochloride (STI571 hydrochloride) delivers robust, multi-target tyrosine kinase inhibition for cancer research, enabling precise modulation of signaling pathways in cell and animal models. This guide translates cutting-edge mechanistic insights and workflow-tested protocols into actionable strategies for chronic myelogenous leukemia and gastrointestinal stromal tumor research.

• Strategic Macrophage Depletion: Unlocking CRC Immunotherapy

  2026-04-26

  Explore how in vivo macrophage depletion with Clodronate Liposomes redefines translational immuno-oncology. This thought-leadership article integrates mechanistic findings on CCL7+ tumor-associated macrophages and resistance to immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC), offering actionable guidance for experimental design and translational research strategies. By contextualizing APExBIO’s Clodronate Liposomes within the latest literature and advanced workflows, the article highlights best practices, protocol parameters, and future outlook—bridging the gap between bench discovery and clinical potential.

• TPCA-1 in Context: Decoding IKK-2 Inhibition for Cell Death

  2026-04-25

  Explore how TPCA-1, a selective IKK-2 inhibitor, enables advanced dissection of cell death and inflammatory signaling. This article uniquely integrates mechanistic insight from recent RIPK1 studies to inform assay design and deepen understanding for inflammation research.

• Applied Workflows with the HyperScribe T7 High Yield Cy3 RNA

  2026-04-24

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit from APExBIO empowers researchers to generate highly fluorescent, customizable RNA probes for advanced RNA detection workflows. This article details experimental protocols, workflow optimizations, and troubleshooting strategies, drawing actionable connections to recent breakthroughs in mRNA delivery and probe design.

• (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl) Urea: Reliable A

  2026-04-24

  This article addresses key workflow challenges in cell viability, proliferation, and cytotoxicity assays by highlighting the validated performance of (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (SKU A8959). Drawing from recent mechanistic research and product quality data, it guides researchers in maximizing reproducibility and assay interpretability using this APExBIO fluorinated phenyl urea compound.

• Tacalcitol Monohydrate: Precision Modulation of NGF and Cell

  2026-04-23

  Explore how Tacalcitol monohydrate, a synthetic analog of vitamin D3, drives targeted NGF induction and cell cycle control for advanced dermatological and oncological research. This article offers novel insights into mechanistic selectivity and experimental optimization.

• Estradiol Benzoate (SKU B1941): Precision for ERα-Driven Ass

  2026-04-23

  This article delivers scenario-driven guidance for biomedical researchers seeking reproducibility in estrogen receptor alpha (ERα) signaling and hormone receptor binding assays. By dissecting common laboratory challenges, we illustrate how Estradiol Benzoate (SKU B1941) from APExBIO offers validated consistency, high purity, and workflow safety for robust data acquisition.

• CHK1 Inhibition in Breast Cancer: ER/PR Status Determines Ef

  2026-04-22

  This study dissects how the response to CHK1 inhibition in breast cancer is dictated by estrogen and progesterone receptor status. The findings clarify when and why CHK1 blockade enhances chemosensitivity or acts as a single-agent antitumor strategy, deepening understanding of molecularly targeted therapy for heterogeneous tumors.

• SIS3 Smad3 Inhibitor: Uncovering New Frontiers in Fibrosis a

  2026-04-22

  Discover how SIS3, a selective Smad3 inhibitor, enables breakthrough research in fibrosis and osteoarthritis by targeting the TGF-β signaling pathway. Explore unique mechanistic insights, protocol guidance, and translational opportunities informed by recent peer-reviewed evidence.

454 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page